Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this interesting cytokine might be developed in the future.

This project follows on the success of the book "25 years of p53", published by Springer in 2006. Since this publication, there have been considerable advances on the potential application of p53 into the clinics. The goal of this book is to capture these developments and to appeal to a clinical and medical audience beyond the one which was the primary target of "25 years of p53".

Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy. In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations. Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection). Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.

The second edition of this book serves both as an introductory and reference book focusing on the field of metastatic bone disease. Featuring contributions from experts in the field, this volume describes the molecular and cellular mechanisms involved in the formation of bone metastases, presents the newer advances made in the understanding of the clinical picture and symptoms of patients, analyses the role of bone markers in research and clinical practice and deals with all aspects of imaging modalities applied for the detection and evaluation of bone metastases. Moreover, the use of all available treatment methods, such as radiotherapy, surgery and systemic treatments for the management of patients with metastatic bone disease is discussed in detail. Overall this volume presents a thorough overview of all aspects of metastatic bone disease and provides a comprehensive and concise information resource for researchers, oncologists, orthopaedic surgeons and clinicians dealing with patients with metastatic bone disease.

This volume presents methods and protocols on modern analysis of steroid receptor and prostate cancer function. Chapters detail androgen, androgen receptor action, anti-androgen enzalutamide, in vitro and in vivo models, imaging, gene fusions, and help facilitate studies with novel drugs including anti-androgens and chemotherapeutics. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Prostate Cancer: Methods and Protocols aims to provide easily reproducible techniques.

Triazenes: Synthesis and Chemical Properties.- Mechanisms of the Biological Actions of Triazenes.- Triazenes and Triazene N-Oxides: Antitumour Action in Animal Tumour Systems.- Antimestastatic Action of Triazene Derivatives.- Effects of Triazenes on Immune Responses.- Xenogenization of Experimental Tumors by Triazene Derivatives.- The Metabolism of Antineoplastic Triazenes.- Notes on the Metabolism, Pharmacokinetics and Mode of Action of N-Methyl and N-Ethyl-Triazenes in Relation to Their Pharmacological Activity.- Clinical Use of Triazenes.- Clinical Studies with the p-Carboxyl-Dimethyl-Phenyl-Triazene CB10-277.- Triazenes: Therapeutic Considerations and Perspectives.- Antitumor Imidazotetrazines: Prodrugs Targeted to the Major Groove of DNA.- O6-Alkylguanine-DNA-Alkyltransferase Gene Expression and the Cytotoxicity of Triazenes.- N-Methylmelamines, a Unique Class of Anti-Tumour Agents?.- Experimental Background and Early Clinical Studies with Imidazotetrazine Derivatives.- 'O6-Alkylguanine-DNA-Alkyltransferase: Significance, Methods of Measurement and Some Human Tumor and Normal Tissue Levels' (Contributions of the Workshop).- Summary of Poster-Sessions.- Contributors.

Billions of dollars are spent every year on research into targeted therapies for cancer. That's why it's more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality.

The purpose of this book is to examine the etiology of cancer in large human populations using mathematical models developed from an inter-disciplinary perspective of the population epidemiological, biodemographic, genetic and physiological basis of the mechanisms of cancer initiation and progression. In addition an investigation of how the basic mechanism of tumor initiation relates to general processes of senescence and to other major chronic diseases (e.g., heart disease and stroke) will be conducted.

This thesis focuses on the development of gold- and non-classical platinum-based anti-cancer agents that display distinctively different anti-cancer mechanisms compared to the commonly used cisplatin. These metal complexes contain N-heterocyclic carbene (NHC) ligands which are able to form strong M-C(NHC) bonds, conferring high stability and favorable lipophilicity, reactivity and binding specificity of metal complexes on biomolecules. The author demonstrates significant advances made in anti-cancer gold(III), gold(I) and platinum(II) complexes. Detailed chemical synthesis, in vitro and/or in vivo anti-cancer activities are clearly presented including: (i) a class of Au(III) complexes containing a highly fluorescent N^N^N ligand and NHC ligand that simultaneously act as fluorescent thiol "switch-on" probes and anti-cancer agents; (ii) a dinuclear gold(I) complex with a mixed diphosphine and bis(NHC) ligand displaying favorable stability and showing significant inhibition of tumor growth in two independent mice models with no observable side effects; and (iii) a panel of stable luminescent cyclometalated platinum(II) complexes exhibiting high specificity to localize to the endoplasmic reticulum (ER) domain, inducing ER stress and cell apoptosis. These works highlight the clinical potential that gold and platinum complexes offer for cancer treatment.

DNA Tumor Viruses will focus on the DNA viruses in the human population that are associated with cancers. It will cover most of the viruses that are thought to contribute to human malignancy.

This book will represent a comprehensive review of the field of DNA tumor virology. Right now, while there are books out there that cover individual viruses that will be also covered in this book, there is no single book that covers this topic comprehensively.

The main textbook in this market, Fields, which is referred to by both reviewers, covers some of these topics but on a lower level. The only two books that are nearly as comprehensive as this one are Human Tumor Viruses, which was published by the American Society for Microbiology in 1998 and is quite outdated, and Viruses, Cell Transformation, and Cancer, which was published by Elsevier in 2001. Our book will be the only current, comprehensive review of its kind in the market.

This volume will introduce new terminology to the field of oncology, subdividing it into oncokinetics-the mechanics of the tumor cells as they arise and spread throughout the body-and oncodynamics-the impact of abnormal cues generated by tumors on the physiological functioning of the body. The volume will outline the importance of oncodynamics from both a cancer patient's and a caregiver's perspectives, stressing its significant impact on cancer patient functionality and the opportunity that cancer researchers will have to develop cross-disciplinary interactions and predict potential consequences of tumors and/or treatment.

Contents: Gerard Jaouen, Nils Metzler-Nolte : Introduction ; Stephane GIBAUD and Gerard JAOUEN: Arsenic - based drugs: from Fowler's solution to modern anticancer chemotherapy; Ana M. Pizarro, Abraha Habtemariam and Peter J. Sadler : Activation Mechanisms for Organometallic Anticancer Complexes; Angela Casini, Christian G. Hartinger, Alexey A. Nazarov, Paul J. Dyson : Organometallic antitumour agents with alternative modes of action; Elizabeth A. Hillard, Anne Vessieres, Gerard Jaouen : Ferrocene functionalized endocrine modulators for the treatment of cancer; Megan Hogan and Matthias Tacke : Titanocenes - Cytotoxic and Anti-Angiogenic Chemotherapy Against Advanced Renal-Cell Cancer; Seann P. Mulcahy and Eric Meggers : Organometallics as Structural Scaffolds for Enzyme Inhibitor Design; Christophe Biot and Daniel Dive : Bioorganometallic Chemistry and Malaria; Nils Metzler-Nolte : Biomedical applications of organometal-peptide conjugates; Roger Alberto : Organometallic Radiopharmaceuticals; Brian E. Mann : Carbon Monoxide - an essential signaling molecule.

This interdisciplinary thesis introduces a systems biology approach to study the cell fate decision mediated by autophagy. A mathematical model of interaction between Autophagy and Apoptosis in mammalian cells is proposed. In this dynamic model autophagy acts as a gradual response to stress (Rheostat) that delays the initiation of bistable switch of apoptosis to give the cells an opportunity to survive. The author shows that his dynamical model is consistent with existing quantitative measurements of time courses of autophagic responses to cisplatin treatment. To understand the function of this response in cancer cells, he has provided a systems biology experimental framework to study quantitative and dynamical aspects of autophagy in single cancer cells using live-cell imaging and quantitative fluorescence microscopy. This framework can provide new insights on function of autophagic response in cancer cells.

This book provides readers with an overview of the frequent occurrence of asymmetric cell division. Employing a broad range of examples, it highlights how this mode of cell division constitutes the basis of multicellular organism development and how its misregulation can lead to cancer. To underline such developmental correlations, readers will for example gain insights into stem cell fate and tumor growth. In turn, subsequent chapters include descriptions of asymmetric cell division from unicellular organisms to humans in both physiological and pathological conditions. The book also illustrates the importance of this process for evolution and our need to understand the background mechanisms, offering a valuable guide not only for students in the field of developmental biology but also for experienced researchers from neighboring fields.

This volume collects a variety of techniques and methodologies developed to facilitate research on integrin biology and to identify ideal targets and approaches for the treatment of multiple organ diseases, with a focus on cancer in particular. The chapters consecutively describe the tools for structural analysis, identification and detection of integrins as biomarkers, and include thorough laboratory and clinically-related methods on different strategies for generation, synthesis and evaluation of probes, carriers, peptides or small particles for integrin targeting, imaging, and drug delivery. As part of the Methods in Pharmacology and Toxicology series, this book contains the practical details that are invaluable in the laboratory. Authoritative and advantageous, Integrin Targeting Systems for Tumor Diagnosis and Therapy serves readers from a wide spectrum, including researchers and students seeking an overview of existing developments, as well as leading professionals aiming to become more familiar with integrin-related innovative technologies in cancer research.

The "Advances in Cancer Research" series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics including RUNX Genes in Development and Cancer; The RNA Continent; The c-myc Promoter; Designer Self-Assembling Peptide Nanofiber Scaffolds for Study of 3-D Cell Biology and Beyond; and Dendritic Cells in Cancer Immunotherapy.

Managing infections that complicate care of neutropenic patients with leukemia and hematopoietic stem cell recipients has become a distinct specialty. In Managing Infections in Patients with Hematological Malignancies, the authors and editor draw on their extensive expertise while providing a roadmap for hematologists to efficiently manage the complex infections within their patients. The first section of the text reviews viral, bacterial, and fungal pathogens, and provides brief descriptions of the microbes and diseases they cause in patients with hematological malignancies. The second section is devoted to management of infections in patients with the different underlying hematological malignancies, while the third addresses several important topics that are often ignored in most books about infections and hematological malignancies. Managing Infections in Hematological Malignancies is a useful tool for all clinicians and practicing hematologists who treat individual patients and aspire to build stronger infectious diseases programs within their respective cancer centers.

This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology.

With many recent advances, cancer cell culture research is more important than ever before. This timely edition of Cancer Cell Culture: Methods and Protocols covers the basic concepts of cancer cell biology and culture while expanding upon the recent shift in cell culture methods from the generation of new cell lines to the use of primary cells. There are methods to characterize and authenticate cell lines, to isolate and develop specific types of cancer cells, and to develop new cell line models. Functional assays are provided for the evaluation of clonogenicity, cell proliferation, apoptosis, adhesion, migration, invasion, senescence, angiogenesis, and cell cycle parameters. Other methods permit the modification of cells for transfection, drug resistance, immortalization, and transfer in vivo, the co-culture of different cell types, and the detection and treatment of contamination. In this new edition, specific emphasis is placed on safe working practice for both cells and laboratory researchers. These chapters contain the information critical to success - only by good practice and quality control will the results of cancer cell culture improve. Written in the successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and accessible, Cancer Cell Culture: Methods and Protocols serves as a practical guide for scientists of all backgrounds and aims to convey the appropriate sense of fascination associated with this research field.

In this book we have taken a comprehensive look at the subject of familial and hereditary gastric tumors. In particular, the aim of this novel editorial work is to propose the correct management of hereditary diffuse gastric cancer patients, focusing in particular on E-cadherin germline mutations, clinical criteria definition, genetic screening and molecular mechanisms, pathology and microscopic features, surgical treatment and clinical approach for asymptomatic mutation carriers. We also describe other inherited predispositions involving gastric carcinoma.